About: Orphan drugs

EURORDIS: Rare diseases need more centralised processes within the EU
Future improvement of the EU Orphan Medicines Regulation (OMP) could involve more centralised processes for all rare diseases at the EU level, the European Organisation for Rare Diseases (EURORDIS) told EURACTIV in a written interview.
Czech drug policy shifts toward patients with rare diseases
The Czech government has launched a legislative initiative to improve access to most modern medications and rare disease drugs, Health Minister Adam Vojtěch told EURACTIV in an interview, adding that patients are involved in the decision-making process at a very early stage, including in drafting the law.
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.